Clinical Trials Browser

Completed × Has results × binimetinib × Clear all

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

Brain Neoplasms, Soft Tissue Neoplasms

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Brain Neoplasms, Melanoma, Neoplasm Metastasis

Neurofibroma, Neurofibromatosis 1, Peripheral Nervous System Neoplasms, Neurofibromatoses, Neurofibroma, Plexiform

Carcinoma, Non-Small-Cell Lung

Triple Negative Breast Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Spinocerebellar Degenerations, Colorectal Neoplasms

Advanced BRAF Mutant Cancers

Neoplasm Metastasis, Colorectal Neoplasms

Colorectal Neoplasms

Solid Tumors Harboring a BRAF V600 Mutation

Colorectal Neoplasms

Melanoma, Hereditary Sensory and Autonomic Neuropathies

Colorectal Neoplasms

Colorectal Neoplasms

Melanoma, Neoplasm Metastasis, Skin Diseases, Skin Neoplasms

Noonan Syndrome 5, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Colorectal Neoplasms

Adenocarcinoma of Lung

Clinical Trials

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

COLUMBUS

Study of MEK162 for Children With Low-Grade Gliomas

MEK162

Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer

EBRAIN-MEL

NF108-BINI

Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

PALBOBIN

OCEANMIST

KEYNOTE-651

A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer

Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

LOGIC-2

ANCHOR-CRC

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

BEACON CRC

Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

MErCuRIC1

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

SIGNATURE

Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors

A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer